Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Scinai Immunotherapeutics Ltd ADR (SCNI)

$0.24 +0.01 (3.20%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	1.18M
Revenue (ttm)	1.31M
Net Income (ttm)	-8.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.35%
Debt to Equity Ratio	0.02

Volume	145,700
Avg Vol	535,384
Day's Range	N/A - N/A
Shares Out	5.17M
Stochastic %K	42%
Beta	2.08
Analysts	Strong Buy
Price Target	$8.00

Company Profile

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 930 2529

Fax: 972 8 930 2531

Website: www.scinai.com

Address:

Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus, Jerusalem, Israel

Zephix Aug. 19 at 3:24 PM

$SCNI solid support here

0 · Reply

IntentionalTrades Aug. 19 at 3:06 PM

$SCNI Another short play

0 · Reply

focafoca99 Aug. 19 at 2:45 PM

$SCNI executed an ADS ratio change, a reverse split to boost per-share price and aim for Nasdaq compliance.

0 · Reply

ShangVXO Aug. 18 at 3:06 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $SCNI & $TOVX pennies to track

0 · Reply

Richard_Roma Aug. 17 at 12:59 PM

$SCNI lol. This biotrash is a non-stop r/s. This is the third time they've done a 1-10 ,since their horrendous universal flu vaccine goo disaster.

0 · Reply

MJ12 Aug. 14 at 12:04 PM

$SCNI

1 · Reply

MJ12 Aug. 14 at 12:00 PM

$SCNI https://share.google/up1QvcWlQOpt8X99p

0 · Reply

luckysupernova Aug. 11 at 11:50 PM

$SCNI remove the split. Do some share buy back. Show you believe in the company.. or do a Plag type of move. Bite those short sellers. If only..

1 · Reply

CrumbEater Aug. 11 at 5:35 PM

$SCNI they put in for a split already.

1 · Reply

focafoca99 Aug. 10 at 10:52 AM

$SCNI hired Eran Kuratz as head of supply chain and business process administration.

0 · Reply

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Wed, 10 Jun 2026 07:55:00 -0400 - 2 months ago

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Wed, 20 May 2026 07:00:00 -0400 - 3 months ago

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Fri, 15 May 2026 08:05:00 -0400 - 3 months ago

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

2026-04-25T00:50:00.000Z - 4 months ago

Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?

Fri, 24 Apr 2026 10:25:04 -0400 - 4 months ago

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

2026-04-24T12:16:55.000Z - 4 months ago

Scinai Immunotherapeutics announces $2.61M private placement

Fri, 24 Apr 2026 08:00:00 -0400 - 4 months ago

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

2026-04-06T11:17:23.000Z - 4 months ago

Scinai Immunotherapeutics completes strategic reorganization

2026-04-06T11:10:47.000Z - 4 months ago

Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026

Mon, 06 Apr 2026 07:00:00 -0400 - 4 months ago

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Wed, 01 Apr 2026 07:35:00 -0400 - 5 months ago

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

2026-03-19T12:08:05.000Z - 5 months ago

Scinai Immunotherapeutics highlights expanded CDMO platform

Mar 19, 2026, 7:50 AM EDT - 5 months ago

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Mar 16, 2026, 4:05 PM EDT - 5 months ago

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

2026-03-02T14:30:59.000Z - 6 months ago

Scinai Immunotherapeutics signs second amendment to PinCell option agreement

Mar 2, 2026, 9:20 AM EST - 6 months ago

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Feb 25, 2026, 8:11 AM EST - 6 months ago

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Feb 17, 2026, 7:00 AM EST - 6 months ago

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Jan 7, 2026, 7:00 AM EST - 8 months ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Dec 2, 2025, 8:50 AM EST - 9 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

2025-10-06T11:40:52.000Z - 11 months ago

Scinai Immunotherapeutics awarded grant from Israel Innovation Authority

Oct 6, 2025, 7:30 AM EDT - 11 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

2025-07-29T11:31:12.000Z - 1 year ago

Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication

Jul 29, 2025, 7:15 AM EDT - 1 year ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

May 30, 2025, 7:00 AM EDT - 1 year ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 7, 2025, 4:01 PM EDT - 1 year ago

Scinai Announces Annual Financial Results for 2024

May 1, 2025, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Mar 27, 2025, 9:25 AM EDT - 1 year ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

2025-03-05T12:37:36.000Z - 1 year ago

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

Mar 5, 2025, 7:30 AM EST - 1 year ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

2025-03-04T22:30:58.000Z - 1 year ago

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Sep 16, 2024, 7:00 AM EDT - 2 years ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 9, 2024, 11:12 AM EDT - 2 years ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

2024-08-29T10:35:55.000Z - 2 years ago

Scinai Immunotherapeutics regains compliance with Nasdaq

Aug 29, 2024, 6:31 AM EDT - 2 years ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 20, 2024, 9:30 AM EDT - 2 years ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

2024-07-23T11:13:35.000Z - 2 years ago

Scinai Immunotherapeutics’ IL-17 nanoAb receives positive regulatory feedback

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 15, 2024, 12:31 PM EDT - 2 years ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

2024-07-15T11:10:01.000Z - 2 years ago

Scinai Immunotherapeutics’ psoriasis candidate shows efficacy in study

Jul 15, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

2024-07-08T12:18:12.000Z - 2 years ago

Scinai Immunotherapeutics receives updated LOI from EIB

Jul 8, 2024, 8:14 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 3, 2024, 9:32 AM EDT - 2 years ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

2024-07-02T12:31:36.000Z - 2 years ago

Scinai Immunotherapeutics reports Q1 EPS ($0.001c) vs ($0.003) last year

Jul 2, 2024, 8:12 AM EDT - 2 years ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 7, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

May 24, 2024, 4:01 PM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 15, 2024, 4:01 PM EDT - 2 years ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 6, 2024, 9:21 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Zephix Aug. 19 at 3:24 PM

$SCNI solid support here

0 · Reply

IntentionalTrades Aug. 19 at 3:06 PM

$SCNI Another short play

0 · Reply

focafoca99 Aug. 19 at 2:45 PM

$SCNI executed an ADS ratio change, a reverse split to boost per-share price and aim for Nasdaq compliance.

0 · Reply

ShangVXO Aug. 18 at 3:06 AM

0 · Reply

Richard_Roma Aug. 17 at 12:59 PM

$SCNI lol. This biotrash is a non-stop r/s. This is the third time they've done a 1-10 ,since their horrendous universal flu vaccine goo disaster.

0 · Reply

MJ12 Aug. 14 at 12:04 PM

$SCNI

1 · Reply

MJ12 Aug. 14 at 12:00 PM

$SCNI https://share.google/up1QvcWlQOpt8X99p

0 · Reply

luckysupernova Aug. 11 at 11:50 PM

$SCNI remove the split. Do some share buy back. Show you believe in the company.. or do a Plag type of move. Bite those short sellers. If only..

1 · Reply

CrumbEater Aug. 11 at 5:35 PM

$SCNI they put in for a split already.

1 · Reply

focafoca99 Aug. 10 at 10:52 AM

$SCNI hired Eran Kuratz as head of supply chain and business process administration.

0 · Reply

Bulltrader988 Aug. 10 at 10:51 AM

$SCNI 👃👀 https://www.stocktitan.net/news/SCNI/scinai-strengthens-cdmo-leadership-with-appointment-of-eran-kuratz-r2fx9a1hbpyk.html

0 · Reply

Richard_Roma Aug. 4 at 5:32 AM

$SCNI this trash will have to do another reserve split to avoid the stinky pinks... after their bioturd ph3 universal flu vaccine that was effective as salt water, they did 10-1, another 10-1, and probably 25 (or greater) to 1 next

1 · Reply

DiamondDelta Aug. 4 at 1:21 AM

Markets heating up especially low float tickers, After hours started to go crazy, expecting this to continue tomorrow. Keep a close watch on VGAS. Very tight float, took off to near $2 on small volume right at close. I believe VGAS will be tomorrow's top runner.! If you want to make some life changing money keep VGAS on close watch!! $BURU $OPEN $SCNI $ONFO ..66 good looks.

0 · Reply

luckysupernova Aug. 3 at 4:10 PM

$SCNI needs more support to hold .33 and knock out old resistance levels. 1 is possible.

0 · Reply

cntrade1 Aug. 3 at 3:53 PM

$SCNI 👀

0 · Reply

cardinals420 Aug. 3 at 2:43 PM

$SCNI

0 · Reply

Poynting3 Aug. 2 at 8:55 AM

$SCNI This stock was $0.89 on 29th April, and now it's $0.24. The value destruction is staggering, and yet there are people here who think this stock will soon soar to the skies. Cognitive dissonance is one of the most destructive traits that a person can be born with.

2 · Reply

CrumbEater Jul. 31 at 1:14 PM

$SCNI times ticking...I don't think they got the feng grant or they would of announced it to meet nasdaq rules because it has to stay above 1$ for 10days. I am guessing mid August they are going to announce R/S

0 · Reply

luckysupernova Jul. 31 at 9:15 AM

$SCNI bring out the pom poms.

0 · Reply

Richard_Roma Jul. 28 at 3:43 PM

$SCNI never leaves the gutter, bagholders slide into it.

0 · Reply

luckysupernova Jul. 27 at 11:47 AM

$SCNI time to get up out the gutter.

0 · Reply

Richard_Roma Jul. 20 at 2:27 PM

$SCNI a top bioturd for exec enrichment with nothing to show for it.

0 · Reply

1.0.0